Thomas Steyer’s Jazz Pharmaceuticals JAZZ Stock Holding History

Thomas Steyer’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-150,000	Closed	-$21.9M	–	176
2023 Q1	$21.9M	Sell	150,000 -79,800	-35%	-$11.8M	0.12%	78
2022 Q4	$36.6M	Sell	229,800 -307,700	-57%	-$45.1M	0.22%	70
2022 Q3	$71.6M	Sell	537,500 -382,600	-42%	-$58.2M	0.39%	65
2022 Q2	$144M	Buy	920,100 +591,100	+180%	+$91M	0.78%	42
2022 Q1	$51.2M	Sell	329,000 -102,021	-24%	-$14.8M	0.25%	69
2021 Q4	$54.9M	Sell	431,021 -143,886	-25%	-$18.9M	0.27%	64
2021 Q3	$74.9M	Buy	+574,907	New	+$86.9M	0.35%	61

Other funds holding JAZZ

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

LSV Asset Management Chicago, Illinois $55.1B AUM 45.38% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return

PCM

Polaris Capital Management Boston, Massachusetts $1.06B AUM 40.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Thomas Steyer's JAZZ Position: Q2 2023 in Review

Thomas Steyer sold out of Jazz Pharmaceuticals (JAZZ) in Q2 2023, closing a stake of 150,000 shares — an estimated $21.9M sold.

Thomas Steyer first reported a position in JAZZ in Q3 2021 and held it in 7 quarters. The position peaked at $144M in Q2 2022. 472 funds tracked by Wall St. Rank hold JAZZ as of Q2 2023.

Thomas Steyer reported no remaining Jazz Pharmaceuticals position as of Q2 2023 after selling out during the quarter.
Thomas Steyer sold 150,000 Jazz Pharmaceuticals shares in Q2 2023, an estimated $21.9M.
Thomas Steyer first reported a position in Jazz Pharmaceuticals in Q3 2021 and held it in 7 quarters.
Thomas Steyer's Jazz Pharmaceuticals position peaked at $144M in Q2 2022.
472 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2023.

Based on Farallon Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.